This week in techniques

Approach

Summary

Licensing status

Publication and contact information

Drug platforms

Sialic acid binding Ig-like lectin (SIGLEC)-engaging, tolerance-inducing antigenic liposomes (STALs) to suppress antibody response

Mouse studies identified STALs that could help treat autoimmunity and inflammation. In mice, STALs displaying a protein antigen plus a CD22 ligand, which inhibits autoimmunity, decreased the antigen-specific antibody response during an antigen challenge compared with STALs that only displayed the protein antigen. STALs that had a CD22 ligand inhibited the antibody response by inducing B cell apoptosis. In a mouse model for hemophilia, STALs displaying factor VIII plus a CD22 ligand decreased anti-factor VIII antibody production and bleeding compared with CD22-lacking liposomes. Next steps could include testing the STALs in additional disease indications.

SciBX 6(25); doi:10.1038/scibx.2013.640
Published online June 27, 2013

Patent and licensing status unavailable

Macauley, M.S. et al. J. Clin. Invest.; published online June 3, 2013;
doi:10.1172/JCI69187
Contact: James C. Paulson,
The Scripps Research Institute,
La Jolla, Calif.
e-mail:
jpaulson@scripps.edu